Skip to main navigation
Skip to content Larimar Therapeutics
Larimar Therapeutics Mobile Menu Toggle navigation
Larimar Therapeutics
  • About Larimar
    • Company Overview
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • Scientific Approach
    • Publications
  • Our Programs
    • Pipeline
    • CTI-1601
    • Expanded Access Policy
  • Our Partners
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • News
  • Contact
    • Contact Us
    • Directions
  • About Larimar
    • Company Overview
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • Scientific Approach
    • Publications
  • Our Programs
    • Pipeline
    • CTI-1601
    • Expanded Access Policy
  • Our Partners
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • News
  • Contact
    • Contact Us
    • Directions

SEC Filing Details

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
    • Upcoming events
    • Presentations
    • Past Events
  • FINANCIALS & FILINGS
    • SEC Filings
    • Annual Reports & Proxy Materials
    • Form 8937
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Investor FAQs
  • Contact Us
  • Email Alerts

Shareholder Tools

  • Email Alerts
  • RSS
  • Print
  • Share
 

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • Email
  • RSS

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
    • Upcoming events
    • Presentations
    • Past Events
  • FINANCIALS & FILINGS
    • SEC Filings
    • Annual Reports & Proxy Materials
    • Form 8937
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Investor FAQs
  • Contact Us
  • Email Alerts

SEC Filing Details

SEC Filing Details

Document Details

Form
10-K
Filing Date
Mar 14, 2023
Document Date
Dec 31, 2022
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Larimar Therapeutics, Inc.
Issuer
LARIMAR THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT

© 2023 Larimar Therapeutics, Inc. All rights reserved.
LARIMAR and LARIMAR THERAPEUTICS are trademarks of Larimar Therapeutics, Inc.

Footer Nav

  • Terms of use
  • Privacy Policy
  • Site Credits